Nomura Securities Starts Neurocrine Bio. (NBIX) at Buy

January 8, 2014 7:44 AM EST Send to a Friend
Nomura Securities initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy. PT $23.00.

Analyst Ian Somaiya comments: "Neurocrine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login